iX Biopharma has high hopes for drug spin-off
After the planned HK listing of its pharmaceutical and medical cannabis business, the company will focus on nutraceuticals. BY JANICE HENG
CATALIST-LISTED iX Biopharma wishes investors would focus less on its current topline or bottom-line, and more on the potential of its products and patented technology.
This search for understanding investors is one reason it is looking to spin off its pharmaceutical and medicinal cannabis business for a listing in Hong Kong, said director of corporate affairs Yee Chia Hsing.
"The type of conversation that they have (in Hong Kong) is very different. They don't ask you about when you turn profitable ... They talk about your drug pipeline, they try to understand the size of the market."
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
JPMorgan looks to fend off Goldman and other private credit for US$1 billion
China’s top airlines improve balance sheet in Q1; outlook positive for May Day
Stablecoin issuer Tether invests US$200 million in brain-computer interface company
Yahoo to lay off staff in Singapore as it shifts to content curation
US: Wall St opens higher on megacap strength, Fed verdict awaited
IReit Global occupancy rate grows to 91.5% in Q1